Posted in Pharmacokinetics on
Roles of Quantitative In Vitro ADME in Toxicology and Risk or Safety Assessment
Hugh Barton, US Environmental Protection Agency
0Read MorePharmacokinetics
Posted in Emerging Technologies on
Replacement Alternative Methods and the Need for New Approaches to Risk Assessment in Relation to Chemicals and Chemical Products
Michael Balls & Robert Combes, FRAME
0Read MorePosted in Overarching Challenges on
The Way Forward: Alternatives – The Future is Now!
Andrew N. Rowan, Humane Society International
0Read MorePosted in Overarching Challenges on
Food for Thought … on Validation
Thomas Hartung, Johns Hopkins Center for Alternatives to Animal Testing
0Read MorePosted in Overarching Challenges on
RISK ASSESSMENT + NEW TECHNOLOGIES: Opportunities to Assure Safety Without Animal Testing and Better Protect Public Health?
Julia Fentem & Carl Westmoreland, Unilever
0Read MorePosted in Skin Sensitization on
Skin Sensitization: What is it? Why is it important? What are the challenges?
Ian Kimber, University of Manchester and G. Frank Gerberick, Procter & Gamble
0Read MorePosted in Emerging Technologies on
Computational Toxicology
Robert Kavlock, US Environmental Protection Agency
0Read MorePosted in Skin Irritation-Skin Corrosion on
The Way Forward for In Vitro Skin Irritation Testing
Patrick Hayden, MatTek Corporation
0Read MorePosted in Emerging Technologies on
The Way Forward for the Three Rs and Systems Biology
Nirmala Bhogal, FRAME
0Read MorePosted in Neurotoxicity on
Alternative Methods for Neurotoxicity
William Mundy, US Environmental Protection Agency
0Read MorePosted in Programs & Policies - US on
Some Considerations as ICCVAM Moves Forward
Martin Stephens, Humane Society of the United States
0Read MorePosted in Programs & Policies - US on
Ruminations on ICCVAM/NICEATM and the Draft NICEATM-ICCVAM Five-Year Plan (2008-2012)
Leonard Schechtmann, Innovative Toxicology Consulting, LLC
0Read MorePosted in Carcinogenicity on
Use of Genetic Toxicology Testing for Predicting Carcinogenicity: A Multi-Stakeholder Approach
By Marilyn J. Aardema, Procter & Gamble
0Read MorePosted in Neurotoxicity on
Why In Vitro Neurotoxicity Approaches Are Not Formally Validated and Used for Regulatory Purposes: The Way Forward
Sandra Coecke & Anna Price, ECVAM
0Read MorePosted in Acute Systemic Toxicity on
Opportunities and Barriers to the Replacement of Animals in Acute Systemic Toxicity Testing
Troy Seidle, Humane Society of the United States, Humane Society International & Humane Society Legislative Fund
1Read MorePosted in Genotoxicity on
Animal Use in Genetic Toxicity Tests for Identifying Potential Carcinogens
Errol Zeiger, Errol Zeiger Consulting
0Read MorePosted in Genotoxicity on
Use of In Silico Evaluation of Chemical Genotoxicity
Makoto Hayashi, National Institute of Health Sciences (Japan)
0Read MorePosted in Acute Systemic Toxicity on
The ACuteTox Testing Strategy: The Way Forward to Replace the Animal Tests Used Today in the Field of Acute Systemic Toxicity
Cecilia Clemedson, Expertrådet ECB Environmental Competence Ltd
0Read MorePosted in Eye Irritation / Serious Eye Damage on
The Way Forward for Eye Irritation Testing
Chantra Eskes, Valérie Zuang & Thomas Hartung, ECVAM
0Read More